Fischer Medical Ventures Limited FISCHER NSEPHARMA
Company Overview
Fischer Medical Ventures Limited engages in the manufacture, distribution, leasing, and maintenance of medical equipment in India and internationally. Its product portfolio includes magnetic resonance imaging (MRI) systems; preventive health kiosks; e-health access points; software solutions; cancer, TB screening, and handheld x-ray; spincare technology; nutraceuticals; mental health solutions; contactless screening solutions; and CT scan systems, as well as preventive diagnostic devices and ancillary medical instruments. The company was formerly known as Fischer Chemic Limited and changed its name to Fischer Medical Ventures Limited in March 2024. Fischer Medical Ventures Limited was incorporated in 1993 and is headquartered in Chennai, India.
Why Investors Should Care
Net profit has compounded at 28361.6% per year over the last five years.
Revenue has grown at a 1097.9% CAGR over the past five years.
Trades at a P/E of 10.7, below the sector median of 36.4.
Carries low leverage with a debt-to-equity ratio of 0.28.
Recent Developments
- Mar 2026 Revenue of ₹308.58 Cr (+178.8% YoY); net profit ₹31.02 Cr.
- Trailing 12 Months Year-on-year growth — revenue +249.4%, earnings +2468.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 1097.9%, profit CAGR 28361.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1,097.93% |
| 1 Year: | 249.40% |
Compounded Profit Growth
| 5 Years: | 28,361.55% |
| 1 Year: | 2,468.04% |
Stock Price Performance
| 1 Year: | -73.93% |
| 6 Months: | -33.10% |
| 3 Months: | -35.52% |
| 1 Month: | -23.43% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)15.87 · Oversold
P/E of 10.74 is below the sector median of 36.43 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 1097.9% over 5 years.
- Profit CAGR of 28361.6% over 5 years.
CONS
- Trading 78.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 16 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FISCHER Fischer Medical Ventures Limited NSEPHARMA | 25.13 | 10.74 | ₹1,755.80 Cr | 0.15% | 12.64% | 8.07% | 1,097.93% | 28,361.55% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,745.10 | 34.62 | ₹4.19 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,190.00 | 83.58 | ₹2.44 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,553.80 | 72.74 | ₹1.73 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,117.30 | 24.90 | ₹1.11 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 631.35 | 164.41 | ₹1.09 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,600.00 | 52.32 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,012.50 | 99.48 | ₹1.09 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,314.00 | 31.51 | ₹1.06 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 20.79 Cr | 10.12 Cr | 39.66 Cr | 11.75 Cr | 49.17 Cr | 23.44 Cr | 86.31 Cr | 101.10 Cr | 97.73 Cr |
| Cost of Revenue | - | - | - | - | 7.54 Cr | 39.31 Cr | 12.76 Cr | - | 50.17 Cr | 71.03 Cr |
| Gross Profit | - | - | - | - | 4.21 Cr | 9.86 Cr | 10.68 Cr | - | 50.93 Cr | 26.70 Cr |
| Operating Expenses | 0 | 18.28 Cr | 10.33 Cr | 39.16 Cr | 4.27 Cr | 7.87 Cr | 7.19 Cr | 70.09 Cr | 30.13 Cr | 26.63 Cr |
| Operating Income | 0 | 2.33 Cr | -49.00 L | 21.00 L | -6.11 L | 1.99 Cr | 3.49 Cr | 15.71 Cr | 20.79 Cr | 7.73 L |
| EBITDA | 0 | 2.51 Cr | -21.00 L | 50.00 L | 74.84 L | 2.55 Cr | 11.61 Cr | 16.22 Cr | 22.60 Cr | 2.27 Cr |
| Interest Expense | 0 | 5.00 L | 13.00 L | 5.00 L | 6.69 L | 22.63 L | 66.99 L | 92.00 L | 63.71 L | 3.61 Cr |
| Pretax Income | 0 | 2.75 Cr | 7.00 L | 21.00 L | 12.44 L | 1.81 Cr | 10.18 Cr | 17.27 Cr | 21.19 Cr | -2.26 Cr |
| Tax Provision | - | 17.00 L | 19.00 L | -8.00 L | 41.83 L | 50.00 L | 5.17 Cr | 3.36 Cr | 1.95 Cr | 4.86 Cr |
| Net Income | 0 | 2.59 Cr | -12.00 L | 29.00 L | -29.39 L | 1.31 Cr | 5.01 Cr | 13.90 Cr | 19.23 Cr | -7.12 Cr |
| Diluted EPS | 0.00 | 0.05 | -0.00 | 0.01 | -0.01 | 0.01 | 0.09 | 0.21 | 0.29 | -0.11 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 17.95 L | 20.98 Cr | 110.70 Cr | 308.58 Cr |
| Cost of Revenue | - | 0 | 16.45 Cr | 91.59 Cr | 195.59 Cr |
| Gross Profit | - | 17.95 L | 4.53 Cr | 19.11 Cr | 112.99 Cr |
| Operating Expenses | - | 16.42 L | 2.85 Cr | 17.43 Cr | 72.88 Cr |
| Operating Income | - | 1.53 L | 1.68 Cr | 1.68 Cr | 40.10 Cr |
| EBITDA | - | 1.52 L | 2.36 Cr | 4.32 Cr | 55.18 Cr |
| Interest Expense | - | 1.65 L | 6.76 L | 46.68 L | 5.83 Cr |
| Pretax Income | - | -13,000 | 2.11 Cr | 2.22 Cr | 46.36 Cr |
| Tax Provision | - | 3.52 L | 27.33 L | 1.01 Cr | 15.34 Cr |
| Net Income | - | -3.65 L | 1.84 Cr | 1.21 Cr | 31.02 Cr |
| Diluted EPS | -1.35 | -0.21 | 1.08 | 0.02 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 35.35 L | 86.32 Cr | 457.37 Cr | 671.01 Cr |
| Current Assets | - | 24.79 L | 70.41 Cr | 365.29 Cr | 417.59 Cr |
| Cash & Equivalents | - | 3.58 L | 94.83 L | 104.26 Cr | 11.89 Cr |
| Inventory | - | 0 | 4.48 Cr | 9.16 Cr | 12.66 Cr |
| Receivables | - | 17.06 L | 22.87 Cr | 76.07 Cr | 288.80 Cr |
| Total Liabilities | - | 61.95 L | 5.21 Cr | 119.50 Cr | 285.87 Cr |
| Current Liabilities | - | 4.78 L | 3.83 Cr | 81.57 Cr | 258.03 Cr |
| Long Term Debt | - | 57.17 L | 0 | 19.73 Cr | 26.09 L |
| Total Debt | - | 57.17 L | 1.68 Cr | 85.37 Cr | 107.08 Cr |
| Total Equity | - | -26.60 L | 81.11 Cr | 337.52 Cr | 384.39 Cr |
| Shares Outstanding | - | 17.20 L | 5.35 Cr | 63.80 Cr | 65.45 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -14.59 L | -7.35 Cr | -86.25 Cr | -101.27 Cr |
| Investing Cash Flow | - | 0 | -31.39 Cr | -125.36 Cr | -5.22 Cr |
| Financing Cash Flow | - | 16.60 L | 37.06 Cr | 314.92 Cr | 14.11 Cr |
| Capital Expenditure | - | - | -48.49 L | -5.99 Cr | -1.31 Cr |
| Free Cash Flow | - | -14.59 L | -7.84 Cr | -92.24 Cr | -102.58 Cr |
| Net Change in Cash | - | 2.01 L | -1.68 Cr | 103.31 Cr | -92.37 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 100.0% | 21.6% | 17.3% | 36.6% |
| Operating Margin % | - | 8.5% | 8.0% | 1.5% | 13.0% |
| Net Margin % | - | -20.3% | 8.8% | 1.1% | 10.1% |
| ROE % | - | 13.7% | 2.3% | 0.4% | 8.1% |
| ROCE % | - | 5.0% | 2.0% | 0.4% | 9.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FISCHER
Georg Fischer (SWX:GF) Stock Looks Near Fair Value After Its 33% Run - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOTnMxU2tMQ0VDS09ocnVkemdYYkVTc0hrNkRycjlzTGxjWmp2eDJzMm43NThSM19EYjNPUGRmZ1liVWZ5ck1oQU5LX2xFQXRIT2VTU25hSHp0a3poUWNGNVpXZzJ1X2RUbDZNNGx0eDhUNmg4Z04zdVM1c3RMNDl2c1FpWXAwZU1rQzV2RE…
IDT CFO Marcelo Fischer sells $760,847 in class B common stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQV2tPOXlNcDg2MVkzbnZTcDVKYXpIcks2MzZyUy1kR0xfMF8zSzlXUTA3RThCVS1SVHVEaDV3TDVETXhtZEdFYUFNWUVSWlFVU1pQS1FDc1F6Q3lDLVNHNnkxdUxaNldBem44WDJDd0pvRENsMEF5MnlBWjEyU19XTTVwTDVnN1ZqZGI4Qj…
Engaging In Options Activity, MARCELO FISCHER Exercises Options Valued At $186K In IDT - Benzinga
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNZEhUZVU5SDY0YzFzYXNNeUFKcXd2Sl9xVVcxR2Npeld2Z1AxSVkwUFFWS3J0YlByX2ZzWmhnRHk4SFN6RHE5QVpHT0h2bG9XdERPZFgtTDE5N3A5bXFMOG1FQWFjZmt1YWdCaDl1aXZkWnE2QUVEUlBaUFQwSkk5NzlmMXBrbkgyLVprSD…
CFO sells 9,333 shares at IDT (IDT) alongside an exercise of 4,257 stock options. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNcTY2SUlTb2ZJN3JkSEtXS0RQRU03UmhJczZHWGRqeGdVT3JFbnNRa0FUWFVqamVuMF9mOVBocVRfUmRyUTBRMVpQZFZzU1ppMFdzVXFadTJSOGZ6Y1UtMnJjQUF4TmJ4T2ZyNFJhQ2hRTklPdURJaHFnTTBKOVAyMlZxY1dXT2U5N0cwWH…
Fischer Medical Ventures Share Price Today Drops to Rs 25.63 - Univest
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxOT182aU1WLVZOaFlRUnpCYkJpNkt4X3RmSDQ5X3lrdW5TVlpLUXNmQWZvekFtQkRfVjZDWU12NjZXaGlCQkFSaHRXT1hyVkpBN1hsekNpajgzQUp2bUloSnBnREhoUHAzQ0o5UGpROG0tdTNXR0RQOGk0Y28yczQyWTU2UnpPWWJ2?oc=5"…
Fischer Medical Ventures Share Price and RSI - Kalkine India
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQeV9oeGFaOVllOHM3c3dGYVhpTWVzMVdCMHpXVmRCTmRlbndHdkZ6TW9YOGs0ejdhU3ctYzJFQjktdUUwMmpacDdUUXBOR3Y3UUdCQUhzSDhWRl9ybk1pUnM0Yk1XaDJpamthUWM3R2FncU5SNTdJZmJmN3c3TFFCeDZiTnh4dmxuRUZQQW…
FISCHER — Frequently Asked Questions
What is the current share price of Fischer Medical Ventures Limited (FISCHER)?
As of 2026-10-23 04:58 IST, Fischer Medical Ventures Limited (FISCHER) trades at ₹25.13 on NSE. Its 52-week range is ₹25.13 to ₹117.53.
What is the market capitalisation of FISCHER?
Fischer Medical Ventures Limited (FISCHER) has a market capitalisation of ₹1,755.80 Cr on NSE.
What is the P/E ratio of FISCHER?
FISCHER trades at a trailing price-to-earnings (P/E) ratio of 10.74. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 5.10.
Does FISCHER pay a dividend?
Fischer Medical Ventures Limited (FISCHER) currently offers a dividend yield of 0.15%.
What is the return on equity (ROE) of FISCHER?
FISCHER has a return on equity (ROE) of 8.07%. Its return on capital employed (ROCE) is 12.64%.
Is FISCHER a good stock to buy?
This page provides a data-driven analysis of Fischer Medical Ventures Limited (FISCHER), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.